Rockefeller University v. Ligand Pharmaceuticals Inc.

581 F. Supp. 2d 461, 2008 U.S. Dist. LEXIS 40528, 2008 WL 2139148
CourtDistrict Court, S.D. New York
DecidedMay 19, 2008
Docket08 Civ. 2755(PKC)
StatusPublished
Cited by17 cases

This text of 581 F. Supp. 2d 461 (Rockefeller University v. Ligand Pharmaceuticals Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Rockefeller University v. Ligand Pharmaceuticals Inc., 581 F. Supp. 2d 461, 2008 U.S. Dist. LEXIS 40528, 2008 WL 2139148 (S.D.N.Y. 2008).

Opinion

MEMORANDUM AND ORDER

P. KEVIN CASTEL, District Judge.

Defendant Ligand Pharmaceuticals Incorporated (“Ligand”) has moved to dismiss this action for lack of personal jurisdiction and improper venue. Alternatively, it seeks to transfer the action to the Southern District of California, pursuant to 28 U.S.C. § 1404(a). For the reasons set forth below, this court concludes that there is general jurisdiction over Ligand, venue is proper and the section 1404(a) factors do not favor transfer to another district. The motion is denied.

Background

The action was commenced in Supreme Court New York County by The Rockefeller University (the “University”) and timely removed to this Court by Ligand invoking diversity jurisdiction. 28 U.S.C. §§ 1332, 1441(b). 1 The University alleges that in 1992 it licensed to Ligand certain technology, know-how and inventions relating to the tools to screen therapeutic drugs. It further alleges that Ligand granted a sublicense to a predecessor-in-interest to SmithKline Beecham (“SKB”) and that Ligand has received milestone payments from SKB. The University alleges that Ligand breached the 1992 licensing agreement by failing to pay to the University its contractual share of the milestone payments.

The licensing agreement between the University and Ligand and made as of September 30, 1992 (the “Agreement”), recites that Ligand is a Delaware corporation with its principal place of business in San Diego, California, and that the University is a non-profit educational corporation organized under the laws of the state of New York with an office in Manhattan. The Agreement refers to the “valuable technology and know-how relating to pep-tidyl hormone mediated gene expression” developed by “Dr. James Darnell and his colleagues at Rockefeller and at NYU.” The licensed territory is defined as the “entire world.” The agreement contains a New York choice of law provision.

In June 1992, Ligand’s representatives were invited to New York to meet with representatives of the University in connection with the negotiation of what eventually became the licensing agreement. (Letter of Giesar, June 17, 1992.) Following execution of the agreement, Dr. Darnell wrote to Ligand’s Director of Research thanking him for his visit to the University^ (Letter of Darnell, Dec. 22, 1992.) A January 25, 1993 meeting was scheduled between Dr. Darnell and Dr. John Rosen of Ligand and Darnell’s administrative secretary arranged for housing accommodations for Rosen at a University facility. (Letter of Cousseau, Jan. 20,1993.)

Ligand argues that there is no general or specific jurisdiction over it. It asserts *464 that those Ligand employees who performed work pursuant to the agreement with SKB’s predecessor did so in California and not in New York. (Decl. of Marsch-ke, Mar. 20, 2008.) It states that, at the time of suit, it was not present in New York on a systematic or continuous basis. It neither owns nor leases real estate in New York; it maintains no telephone listing and has no employees in New York. (Decl. of Warfield-Graham, Mar. 19, 2008.) It concedes that it is authorized to do business in this state, but disputes whether such authorization is, alone, a sufficient basis for jurisdiction. Ligand sold the product AVINZA in New York from about 1998 to about 2007, but asserts that it no longer sells the product and that the product has nothing to do with the subject matter of this lawsuit. (Id.)

Discussion

A. Personal Jurisdiction

On a defendant’s motion to dismiss for lack of personal jurisdiction, the plaintiff bears the burden of demonstrating that the court has jurisdiction. See In re Magnetic Audiotape Antitrust Litig., 334 F.3d 204, 206 (2d Cir.2003) (per curiam). “[T]he nature of the plaintiffs obligation varies depending on the procedural posture of the litigation.” Ball v. Metalurgy Hobokerir-Overpelt, S.A, 902 F.2d 194, 197 (2d Cir.1990). Prior to discovery, a plaintiff may defeat a Rule 12(b)(2) motion by “pleading in good faith legally sufficient allegations of jurisdiction.” Id. (citation omitted). Plaintiff must make a “prima facie showing” of personal jurisdiction. Jazini v. Nissan Motor Co., Ltd., 148 F.3d 181, 184 (2d Cir.1998) (quotation omitted).

Personal jurisdiction may be exercised over any defendant “who could be subjected to the jurisdiction of a court of general jurisdiction in the state where the district court is located.” Rule 4(k)(l)(A), Fed.R.Civ.P. If plaintiff is able to establish a factual predicate for jurisdiction under the laws of the forum state — here, New York — then the court must consider whether the exercise of jurisdiction violates due process. Wiwa v. Royal Dutch Petroleum Co., 226 F.3d 88, 94 (2d Cir.2000).

Under New York’s general jurisdiction statute, N.Y. CPLR § 301, “a foreign corporation is subject to general personal jurisdiction in New York if it is ‘doing business’ in the state.” Wiwa, 226 F.3d at 95. “ ‘[A] corporation is “doing business” and is therefore “present” in New York and subject to personal jurisdiction with respect to any cause of action, related or unrelated to the New York contacts, if it does business in New York, “not occasionally or casually, but with a fair measure of permanence and continuity.” ’ ” Id. (quoting Tauza v. Susquehanna Coal Co., 220 N.Y. 259, 267, 115 N.E. 915 (1917)) (alteration in Wiwa). The corporation must be engaged in “a continuous and systematic course of ‘doing business’ here .... ” Drummer v. Hilton Hotels Int’l, Inc., 19 N.Y.2d 533, 536, 281 N.Y.S.2d 41, 227 N.E.2d 851 (1967). There is no precise test for “doing business” in the state, and courts must look to “the aggregate of the corporation’s activities in the State .... ” Laufer v. Ostrow, 55 N.Y.2d 305, 310, 449 N.Y.S.2d 456, 434 N.E.2d 692 (1982). There are, however, several traditional factors that courts consider when undertaking this analysis, and they are “whether the company has an office in the state, whether it has any bank accounts or other property in the state, whether it has a phone listing in the state, whether it does public relations work there, and whether it has individuals permanently located in the state to promote its interests.” Wiwa, 226 F.3d at 98.

Here, plaintiffs claim of general personal jurisdiction over defendant rests *465 on a theory of consent.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hogan v. Mahabir
S.D. New York, 2022
Aybar v. Aybar
2019 NY Slip Op 412 (Appellate Division of the Supreme Court of New York, 2019)
Amelius v. Grand Imperial LLC
57 Misc. 3d 835 (New York Supreme Court, 2017)
Wilderness USA, Inc. v. DeAngelo Bros. LLC
265 F. Supp. 3d 301 (W.D. New York, 2017)
Minholz v. Lockheed Martin Corp.
227 F. Supp. 3d 249 (N.D. New York, 2016)
Chatwal Hotels & Resorts LLC v. Dollywood Co.
90 F. Supp. 3d 97 (S.D. New York, 2015)
Acorda Therapeutics, Inc. v. Mylan Pharmaceuticals Inc.
78 F. Supp. 3d 572 (D. Delaware, 2015)
United States v. Kolon Industries, Inc.
926 F. Supp. 2d 794 (E.D. Virginia, 2013)
Weinstein v. Kmart Corp.
99 A.D.3d 997 (Appellate Division of the Supreme Court of New York, 2012)
Hunter v. Deutsche Lufthansa AG
863 F. Supp. 2d 190 (E.D. New York, 2012)
Jones v. Koons Automotive, Inc.
752 F. Supp. 2d 670 (D. Maryland, 2010)
MWL Brasil Rodas & Eixos Ltda v. K-IV Enterprises LLC
661 F. Supp. 2d 419 (S.D. New York, 2009)
Marimed Shipping Inc. v. Persian Gulf Shipping Co.
567 F. Supp. 2d 524 (S.D. New York, 2008)

Cite This Page — Counsel Stack

Bluebook (online)
581 F. Supp. 2d 461, 2008 U.S. Dist. LEXIS 40528, 2008 WL 2139148, Counsel Stack Legal Research, https://law.counselstack.com/opinion/rockefeller-university-v-ligand-pharmaceuticals-inc-nysd-2008.